Kodiak Sciences logo
Kodiak Sciences
KOD | NASDAQ
Chart Builder DCF Calculator
$100.73
-$10.46 (-9.41%)
At close: Nov 16, 2026, 4:00 PM ET
$100.73
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:58 PM ET

Kodiak Sciences Company Profile

Company profile explained

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Key Executives

Name Position
Victor Perlroth Co-Founder, Chairman, Chief Executive Officer & President
John A. Borgeson Executive Vice President, Chief Financial Officer & Secretary
Wayne To Chief Technology Officer
Almas Qudrat Chief Quality Officer
Dolly S. Chang Chief Scientific Officer
Hong Liang Senior Vice President of Development
J. Pablo Velazquez-Martin Chief Medical Officer
Laurent Ducay Senior Vice President of Biologics Development & Manufacturing
Stephen Raillard Senior Vice President of Chemical Development & Manufacturing

Latest SEC Filings

Date Type Title
Oct 26, 2026 4 Filing
Oct 23, 2026 4 Filing
Oct 20, 2026 S-3ASR Automatic shelf registration statement of securiti...
Sep 30, 2026 SC 13D/A [Amend] Filing
Sep 30, 2026 4 Filing
Sep 30, 2026 4 Filing
Sep 30, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 28, 2026 8-K Current Report
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Kodiak Sciences
Kodiak Sciences logo
Country United States
IPO Date Oct 4, 2018
Industry Biotechnology
Sector Healthcare
Employees 141
CEO Victor Perlroth

Contact Details

1200 Page Mill Road Palo Alto, California 94304 United States

Stock Details

Ticker Symbol KOD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001468748
CUSIP Number 50015M109
ISIN Number US50015M1099
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.